Clinical Trials Logo

Clinical Trial Details — Status: Active, not recruiting

Administrative data

NCT number NCT03381300
Other study ID # NL57738.000.16
Secondary ID
Status Active, not recruiting
Phase N/A
First received
Last updated
Start date January 1, 2018
Est. completion date November 1, 2071

Study information

Verified date May 2021
Source Radboud University Medical Center
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Rationale: Infertility due is a major concern for girls with Turner syndrome (TS) and their parents. Physicians are often asked about possible options to preserve their fertility. However, despite some experimental case reports, clear evidence for fertility preservation in these girls is lacking and many questions remain. Without evidence on the effectiveness of fertility preservation it cannot routinely be offered to girls with TS. Objective: To investigate the occurrence of live birth in women with TS after ovarian tissue cryopreservation in childhood followed by auto transplantation in adulthood. Study design: A national multicentre exploratory intervention study Study population: Girls diagnosed with Turner Syndrome, aged 2-18 years. Intervention: Ovarian tissue cryopreservation in childhood followed by auto transplantation in adulthood. In order to obtain the ovarian tissue for cryopreservation, all girls must undergo a laparoscopy under general anaesthesia which will be performed in academic/university clinics with paediatric surgery. During the laparoscopic intervention, a unilateral oophorectomy will be performed, thereby leaving the other ovary intact for hormone production, ovulation, spontaneous pregnancies and as an auto transplantation site for cryopreserved-thawed ovarian cortical tissue later on. Furthermore, a small sample of the ovarian cortex will be used to assess the oocyte quality and genetics (e.g. the presence of germ line mosaicism). Oocytes will be karyotyped by using Fluorescence in situ hybridization (FISH). Karyotypic and hormonal data will be collected once at the yearly clinical visit at the paediatric-endocrinologist. Therefore, a buccal swab and one extra blood sample will be taken and evaluated during the routine laboratory evaluation. In the future, auto transplantation of frozen-thawed ovarian cortex strips will be performed.


Description:

Nature and extent of the burden and risks associated with participation, benefit and group relatedness: The primary objective remains to preserve the fertility of the respective (minor) patient, facing a very high risk of premature ovarian insufficiency (POI) of 95-98%. Disadvantages of participating in this study are the potential risk of complications related to the laparoscopic unilateral oophorectomy and/or the unknown effect on future fertility of these girls. Moreover, the procedure might raise false hope in patients (and/or parents) about the chance of getting pregnant after auto transplantation of cryopreserved-thawed ovarian tissue in the future. However, we attempt to overcome this by extensive and objective information provision by both written materials and face to face counselling.


Recruitment information / eligibility

Status Active, not recruiting
Enrollment 106
Est. completion date November 1, 2071
Est. primary completion date December 31, 2022
Accepts healthy volunteers No
Gender Female
Age group 2 Years to 18 Years
Eligibility Inclusion criteria In order to be eligible to participate in this study, a subject must meet all of the following criteria: - Girls and young females with classic Turner (i.e. 45X monosomy) or Turner variants (e.g. 45X / 46XX mosaicism, ring X mosaicism, isochromosome X), - Aged 2 through 18 years, - who completed the diagnostic work up phase of TS including routine cardiac screening*, - whose agreement to participate in this study has been signed by the parents (girls 2-11 years old), - whose agreement to participate in this study has been signed by the patient and her parents (girls 12-17 years old), - whose agreement to participate in this study has been signed by the patient (adolescents of 18 years old). Exclusion Criteria: A potential subject who meets any of the following criteria will be excluded from participation in this study: - Contra-indications for laparoscopic unilateral oophorectomy under general anaesthesia (e.g. severe cardiovascular comorbidity and/or BMI >40 kg/m2)*, - Contra-indications for cryopreservation (i.e. active HIV, hepatitis-B or hepatitis-C infection) - Based on the international Cincinnati Turner Guideline consensus Meeting, July 2016 and consultation of Dutch cardiologists, paediatric-cardiologists and anaesthesists between 2016-2017 there are no absolute cardiovascular contra-indications for surgical intervention and/or pregnancy. Advice against surgical intervention and/or pregnancy should be based on the patient-specific cardiovascular risk profile. The 2% mortality risk due to acute aortic dissection is based on one survey and literature review study that reported the outcomes of 101 pregnancies in patients with TS after oocyte donation. Only 50% of the patients were screened by a cardiologist before entering the oocyte donation programme. Therefore, all girls who want to participate in this study should have completed the diagnostic work up phase of TS including routine cardiac screening and will be screened by a paediatric anaesthesist. Exclusion will be based on the patient specific risk profile. See: References.

Study Design


Intervention

Procedure:
Ovarian tissue cryopreservation
Laparoscopic unilateral oophorectomy followed by cryopreservation of ovarian cortex tissue

Locations

Country Name City State
Netherlands Radboud university medical center. Department Obstetrics & Gynaecology. Nijmegen Gelderland

Sponsors (1)

Lead Sponsor Collaborator
Radboud University Medical Center

Country where clinical trial is conducted

Netherlands, 

References & Publications (1)

Gravholt CH, Andersen NH, Conway GS, Dekkers OM, Geffner ME, Klein KO, Lin AE, Mauras N, Quigley CA, Rubin K, Sandberg DE, Sas TCJ, Silberbach M, Söderström-Anttila V, Stochholm K, van Alfen-van derVelden JA, Woelfle J, Backeljauw PF; International Turner Syndrome Consensus Group. Clinical practice guidelines for the care of girls and women with Turner syndrome: proceedings from the 2016 Cincinnati International Turner Syndrome Meeting. Eur J Endocrinol. 2017 Sep;177(3):G1-G70. doi: 10.1530/EJE-17-0430. Review. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Other Study participation rate The willingness of girls with TS to perform a unilateral oophorectomy for fertility preservation (i.e. the study participation rate) Up to 3 years after inclusion
Other Eligible participants The number of eligible participants Up to 3 years after inclusion
Other Age The age of the participant Up to 3 years after inclusion
Other Buccal cells versus peripheral lymphocytes The incidence of somatic mosaicism (i.e. buccal cells versus peripheral lymphocytes) Up to 3 years after inclusion
Other Ovarian cells versus peripheral lymphocytes The incidence of germ cell mosaicism (i.e. ovarian cells versus peripheral lymphocytes and buccal cells) Up to 3 years after inclusion
Other Serum hormone levels Serum hormone levels (i.e. FSH, Luteinizing hormone (LH), AMH, E2, inhibin B) Up to 3 years after inclusion
Other Complication rate The number of complications related to the laparoscopic procedure Up to 1 year after the laparoscopic procedure
Other Influence of laparoscopic oophorectomy on puberty and/or menarche The incidence of puberty and/or menarche after laparoscopic oophorectomy Up to 10 years after the laparoscopic procedure
Other Incidence of spontaneous pregnancies The incidence of spontaneous pregnancies after laparoscopic oophorectomy Up to 45 years after the laparoscopic procedure
Other Restoration of ovarian function after auto transplantation of ovarian tissue The incidence of menstruation cycle recovery after auto transplantation of cryopreserved-thawed ovarian tissue in the future Up to 2 years after auto transplantation of cryopreserved-thawed ovarian cortical tissue
Other Pregnancies after auto transplantation of ovarian tissue The incidence of pregnancies after auto transplantation of cryopreserved-thawed ovarian tissue in the future Up to 2 years after auto transplantation of cryopreserved-thawed ovarian cortical tissue
Other Ongoing pregnancies after auto transplantation of ovarian tissue The incidence of ongoing pregnancies after auto transplantation of cryopreserved-thawed ovarian tissue in the future Up to 2 years and 3 months after auto transplantation of cryopreserved-thawed ovarian cortical tissue
Other Miscarriages after auto transplantation of ovarian tissue The number of miscarriages after auto transplantation of cryopreserved-thawed ovarian tissue in the future Up to 3 years after auto transplantation of cryopreserved-thawed ovarian cortical tissue
Other Time to pregnancy after auto transplantation of ovarian tissue Time to pregnancy after auto transplantation of cryopreserved-thawed ovarian tissue in the future Up to 2 years after auto transplantation of cryopreserved-thawed ovarian cortical tissue
Other Time to live birth after auto transplantation of ovarian tissue Time to live birth after auto transplantation of cryopreserved-thawed ovarian tissue in the future Up to 3 years after auto transplantation of cryopreserved-thawed ovarian cortical tissue
Primary Live birth ratio (LBR) (main outcome) • Live birth after auto transplantation of cryopreserved-thawed ovarian cortical tissue (i.e. live birth rate or LBR) Up to 3 years after auto transplantation of cryopreserved-thawed ovarian cortical tissue, and up to 45 years after ovarian tissue cryopreservation.
Primary Number of primordial follicles (proximate) The number of primordial follicles found in the ovarian tissue Within 1 month after ovarian tissue cryopreservation
Secondary Patient's age versus LBR The association between patient's age at cryopreservation and LBR Up to 3 years after auto transplantation of cryopreserved-thawed ovarian cortical tissue, and up to 45 years after ovarian tissue cryopreservation.
Secondary Patient's genotype versus LBR The association between patient's genotype and LBR Up to 3 years after auto transplantation of cryopreserved-thawed ovarian cortical tissue, and up to 45 years after ovarian tissue cryopreservation.
Secondary Patient's Anti-Müllerian hormone (AMH) level versus LBR The association between patient's AMH level at cryopreservation and LBR Up to 3 years after auto transplantation of cryopreserved-thawed ovarian cortical tissue, and up to 45 years after ovarian tissue cryopreservation.
Secondary Patient's Follicle-stimulating hormone (FSH) level versus LBR The association between patient's FSH level at cryopreservation and LBR Up to 3 years after auto transplantation of cryopreserved-thawed ovarian cortical tissue, and up to 45 years after ovarian tissue cryopreservation.
See also
  Status Clinical Trial Phase
Completed NCT01734486 - Growth Response in Girls With Turner Syndrome Phase 4
Completed NCT01678261 - X-chromosome Inactivation, Epigenetics and the Transcriptome N/A
Completed NCT01419249 - First Year Growth Response Associated Genetic Markers Validation Phase IV Open-label Study in Growth Hormone Deficient and Turner Syndrome Pre-pubertal Children: the PREDICT Pharmacogenetics Validation Study Phase 4
Completed NCT01518036 - Use of Somatropin in Turner Syndrome Phase 3
Recruiting NCT04948658 - Gonadal Tissue Freezing for Fertility Preservation in Individuals at Risk for Ovarian Dysfunction, Premature Ovarian Insufficiency and Clinically Indicated Gonadectomy
Completed NCT01563926 - Evaluating Acceptance of New Liquid Somatropin Formulation in Children With Growth Hormone Deficiency Phase 3
Completed NCT02787486 - Expanded Noninvasive Genomic Medical Assessment: The Enigma Study
Completed NCT00877942 - Sex Differences in Early Brain Development; Brain Development in Turner Syndrome N/A
Completed NCT00825617 - Quantitative Liver Functions in Turner Syndrome With and Without Hormone Replacement Therapy N/A
Recruiting NCT04463316 - GROWing Up With Rare GENEtic Syndromes
Enrolling by invitation NCT03836300 - Parent and Infant Inter(X)Action Intervention (PIXI) N/A
Completed NCT01245374 - Norditropin NordiFlex® Device Compared to the Device Previously Used by Patients or Parents Phase 4
Completed NCT01322165 - National Registry of Genetically Triggered Thoracic Aortic Aneurysms and Cardiovascular Conditions N/A
Terminated NCT00419107 - Beta Cell Function in Women With Turner Syndrome N/A
Active, not recruiting NCT00625001 - Long Term Follow-up of Bone Mineral Density in Hormone Treated Turner Syndrome N/A
Completed NCT00029159 - The Effect of Androgen and Growth Hormone on Height and Learning in Girls With Turner Syndrome Phase 3
Completed NCT01518062 - Safety of Somatropin and Induction of Puberty With 17-beta-oestradiol in Girls With Turner Syndrome Phase 4
Completed NCT00471731 - Dry Eye in Women With Turner Syndrome and Women With Premature Ovarian Failure N/A
Completed NCT00256126 - Predictive Markers in Growth Hormone Deficiency (GHD) and Turner Syndrome (TS) Children Treated With SAIZEN® Phase 4
Completed NCT03181230 - Health, Fitness, and Quality of Life in Adolescent Girls With Turner Syndrome